| abstract |
The present invention provides molecules, including proteins, more particularly immunoglobulins, whose in vivo half-life is determined by a modified IgG constant domain or FcRn-binding fragment thereof having one or more amino acid residues in at least the CH3 domain. (eg, Fc region or hinge Fc region) (eg, from a human IgG, eg, human IgGl) is altered (increased or decreased). |